On March 30, 2016, the Federal Trade Commission (FTC) filed a complaint in the U.S. District Court for the Eastern District of Pennsylvania against several drug companies for allegedly blocking competition from generic versions of the pain management drugs Opana Er and Lidoderm. This suit marks the first time that the FTC has challenged a “no-AG commitment” in which drug firms agree not to market a lower-cost, authorized generic drug. The FTC seeks remedies under Section 5 of the FTC Act, including restitution or disgorgement of profits. Announcing the complaint, FTC Chairwoman Edith Ramirez stated that the suit “reflects the FTC’s commitment to stopping pay-for-delay agreements … regardless of the form they take.”